http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이방향성 형상기억합금을 이용한 공동 주택용 방화 댐퍼 설계 연구
황성태,이찬희,장진수,변창수,히식수렝,이상욱 순천향대학교 산업기술연구소 2022 순천향 산업기술연구소논문집 Vol.28 No.2
The purpose of this paper is to redesign, compare, and study using bi-directional shape memory alloy spring to compensate for the shortcomings of the existing fire damper performance. Through the spring constant measurement experiment, using the difference in force between the coil spring and the shape memory alloy spring, the damper closes when the set temperature is reached, and opens again when the temperature is lowered. In addition, the internal structure was redesigned through smoke leakage experiments. As a result, semi-permanent usable dampers were modeled.
Tae Jin Kim,In Jae Lee,Byeong Do Song,Sang Chul Lee,Sung Kyu Hong,Seok Soo Byun,Sang Eun Lee,Jong Jin Oh 대한비뇨기종양학회 2016 대한비뇨기종양학회지 Vol.14 No.3
Purpose: To investigate the percentage of pathologic tumor volume (pTPV) among patients who underwent radical prostatectomy (RP). Materials and Methods: We reviewed 3,080 patients who underwent RP between September 2003 and March 2015 and with a postoperative follow-up for more than 1 year. The patient population was stratified into 4 disease risk groups according to tumor stage and pTPV (T2 low volume [T2LV], T2 high volume [T2HV], T3 low volume [T3LV], and T3 high volume [T3HV]). Probability of biochemical recurrence (BCR)-free survival was determined using Kaplan-Meier curves. pTPV was evaluated by Multivariate Cox proportional hazard analysis for predicting BCR. Subgroup analyses were performed according to preoperative risk. Results: The median prostate-specific antigen (PSA) was 7.87 ng/mL, and pTPV was 10%. Among a total of 2,964 patients, T2LV had 1,473 (49.7%), T2HV was 598 (20.2%), T3LV with 199 (6.7%), and T3HV was 694 (23.4%). When comparing T2HV and T3LV, Gleason score and positive surgical margin rate was higher in T3LV. During a 50-month follow-up, BCR-free survival rate was higher in the T2HV group (p<0.001). pTPV was a significant factor to predict BCR in multivariate Cox analysis. In subgroup analyses, T2HV group had similar BCR-free survival rates to T3LV group in the preoperative high risk group while pTPV was significant in the high risk group. Conclusions: pTPV was a significant predictor of BCR among prostate cancer patients after RP, however T2HV had favorable BCR results. Among patients with a preoperative high PSA and Gleason score, T2HV had similar BCR results to T3LV.
( Koung Jin Suh ),( Ki Hwan Kim ),( Ryul Kim ),( Ja Min Byun ),( Miso Kim ),( Jin Hyun Park ),( Bhumsuk Keam ),( Tae Min Kim ),( Jin-soo Kim ),( In Sil Choi ),( Dae Seog Heo ) 대한내과학회 2019 The Korean Journal of Internal Medicine Vol.34 No.4
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear. Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118 patients with DLBCL in first remission with and without surveillance PET/CT (PET/CT [+] group [n = 76] and PET/CT [-] group [n = 42], respectively) were retrospectively analyzed. Results: In a propensity matched cohort with adjustment for International Prognostic Index risk and relapse, the PET/CT (+) group was shown to have similar medical costs as the PET/CT (-) group. Relapse-free survival (RFS) and overall survival (OS) were comparable between the two groups (median RFS not reached [NR] for both groups, p = 0.133; median OS NR, p = 0.542). Among 76 patients with surveillance PET/CT, 31 (40.8%) had findings suggestive of recurrence and 16 of these (51.6%) were later confirmed to have recurrent disease. Fifteen patients (48.4%) were confirmed to not have recurrence after follow-up CT or PET/CT evaluation (n = 10) and biopsy (n = 4). None of the patients with negative PET/CT findings had disease recurrence. Sensitivity, specificity, positive predictive value, and negative predictive value of PET/CT for detection of recurrence were 1, 0.75, 0.52, and 1, respectively. Conclusions: Surveillance PET/CT resulted in similar clinical outcomes and medical costs compared to no surveillance PET/CT. Approximately half of patients with PET/CT findings of recurrence had no recurrence after follow-up imaging and biopsy, which would not have been carried out if PET/CT had not been performed in the first place.
Park, Jin Hyun,Im, Seock-Ah,Byun, Ja Min,Kim, Ki Hwan,Kim, Jin-Soo,Choi, In Sil,Kim, Hee-Jun,Lee, Kyung-Hun,Kim, Tae-Yong,Han, Sae-Won,Oh, Do Youn,Kim, Tae-You 한국유방암학회 2017 Journal of breast cancer Vol.20 No.4
<P><B>Purpose</B></P><P>This study aimed to evaluate the efficacy and safety of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy beyond standard treatment for anthracycline- and taxane-pretreated metastatic breast cancer (MBC).</P><P><B>Methods</B></P><P>We consecutively enrolled 158 MBC patients who underwent CMF chemotherapy in a palliative setting at two academic hospitals in Korea between 2002 and 2016.</P><P><B>Results</B></P><P>The median age of the 158 enrolled patients was 51 years (range, 30–77 years). The enrolled patients were treated with a median of 5 lines of systemic treatment (range, 2–11) before CMF therapy, and the median time from diagnosis of MBC to CMF administration was 36.0 months (range, 7.1–146.7 months). The median number of cycles of CMF treatment was 3 (range, 1–19), and the relative dose intensity was 90.4%. The toxicity profile was mild, with an observed 3.1% of grade 2 and 5.0% of grade 3/4 neutropenia. Among 147 patients (93.0%) whose response to CMF was evaluated, the response rate was 10.9% (16/147), with complete response (CR) in one and partial response (PR) in 15. In addition, the disease control rate (calculated as CR+PR+stable disease) was 44.2% (65/147). The median progression-free survival and overall survival were 3.1 months (95% confidence interval [CI], 2.7–3.6) and 9.4 months (95% CI, 7.1–11.6), respectively.</P><P><B>Conclusion</B></P><P>CMF therapy is effective and tolerable as salvage treatment for heavily pretreated MBC.</P>
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Lee, Woo-Jin,Lee, Soon-Tae,Moon, Jangsup,Sunwoo, Jun-Sang,Byun, Jung-Ick,Lim, Jung-Ah,Kim, Tae-Joon,Shin, Yong-Won,Lee, Keon-Joo,Jun, Jin-Sun,Lee, Han Sang,Kim, Soyun,Park, Kyung-Il,Jung, Keun-Hwa,Jun Springer-Verlag 2016 Neurotherapeutics Vol.13 No.4
<P>A considerable portion of autoimmune encephalitis (AE) does not respond to conventional immunotherapies and subsequently has poor outcomes. We aimed to determine the efficacy of tocilizumab, an anti-interleukin-6 antibody, in rituximab-refractory AE compared with other treatment options. From an institutional cohort of AE, 91 patients with inadequate clinical response to first-line immunotherapy and following rituximab were retrospectively reviewed. Patients were grouped according to their further immunotherapy strategies. Thirty (33.0 %) patients were included in the tocilizumab group, 31 (34.0 %) in the additional rituximab group, and 30 (33.0 %) in the observation group. Outcomes were defined as the favorable modified Rankin Scale scores (aecurrency sign2) at 1 and 2 months from the initiation of each treatment strategy and at the last follow-up. Favorable clinical response (improvement of the modified Rankin Scale scores by aeyen 2 points or achievement of the mRS scores aecurrency sign 2) at the last follow-up was also analyzed. The tocilizumab group showed more frequent favorable mRS scores at 2 months from treatment initiation and at the last follow-up compared with those at the relevant time points of the remaining groups. The majority (89.5 %) of the patients with clinical improvement at 1 month from tocilizumab treatment maintained a long-term favorable clinical response. No serious adverse effects of rituximab or tocilizumab were reported. Therefore, we suggest that tocilizumab might be a good treatment strategy for treating AE refractory to conventional immunotherapies and rituximab. The tocilizumab-mediated clinical improvement manifests as early at 1 month after treatment initiation.</P>